CJC-1295 and Ipamorelin Blend: Dual GH Axis Receptor Activation Studies
Overview of Compound Mechanisms
CJC-1295 and ipamorelin represent distinct classes of growth hormone axis modulators that demonstrate complementary receptor pharmacology profiles in controlled laboratory environments. Published in vitro research characterizes their molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under standardized assay conditions.
Ipamorelin functions as a selective growth hormone secretagogue receptor 1a (GHSR-1a) agonist, demonstrating specific binding characteristics within class A G-protein coupled receptor frameworks. CJC-1295 operates through growth hormone-releasing hormone receptor (GHRH-R) activation, engaging adenylyl cyclase-dependent signaling cascades in appropriate cellular model systems.
Receptor Pharmacology and Mechanism of Action
GHSR-1a Activation Profile
Ipamorelin demonstrates selective GHSR-1a engagement through Gq/11-coupled calcium mobilization pathways in transfected cell line models. Competitive radioligand binding assays reveal specific receptor occupancy with minimal cross-reactivity toward related GPCR subtypes. Functional calcium flux measurements in CHO-K1 cells expressing recombinant GHSR-1a demonstrate concentration-dependent activation profiles with EC50 values typically ranging from 38-74 nM across multiple independent assay systems.
Intracellular calcium imaging studies using Fura-2 fluorescence protocols show rapid onset calcium transients following ipamorelin exposure in GHSR-1a-positive cell populations. Peak calcium responses occur within 30-60 seconds of compound addition, indicating efficient receptor coupling to phospholipase C-beta activation cascades.
GHRH Receptor Signaling Mechanisms
CJC-1295 functions as a selective GHRH receptor agonist, demonstrating high-affinity binding to class B GPCRs coupled to Gs-protein signaling pathways. Adenylyl cyclase activation assays in HEK-293 cells expressing recombinant GHRH receptors show dose-dependent cAMP accumulation with EC50 values approximately 0.1-0.3 nM in standard 30-minute incubation protocols.
Protein kinase A (PKA) activation downstream of cAMP elevation demonstrates characteristic phosphorylation patterns of CREB transcription factors, as measured through Western blot analysis of phospho-CREB (Ser133) expression in responsive cell model systems. Time-course studies reveal maximal CREB phosphorylation occurring 15-30 minutes following CJC-1295 exposure.
Binding Affinity and Selectivity Profiles
Competitive Binding Characteristics
Radioligand competition assays utilizing [125I]-ghrelin demonstrate ipamorelin's competitive inhibition profile at GHSR-1a sites with Ki values ranging from 7.7-25.2 nM across different experimental conditions. Selectivity screening against 40+ receptor subtypes confirms minimal off-target binding activity at concentrations up to 10 μM.
CJC-1295 exhibits nanomolar binding affinity for GHRH receptors in membrane preparations from pituitary adenoma cell lines. Saturation binding experiments using [125I]-GHRH demonstrate competitive displacement with Kd values consistently below 1 nM, indicating high receptor affinity characteristics.
Functional Selectivity Assessment
Pathway-selective activation studies reveal distinct signaling preferences between the two compounds. Ipamorelin preferentially activates calcium-dependent protein kinase C isoforms while demonstrating minimal cAMP elevation in GHSR-1a-expressing systems. Conversely, CJC-1295 shows selective adenylyl cyclase activation without significant calcium mobilization in GHRH receptor-positive cell models.
Enzyme Kinetics and Metabolic Stability
Proteolytic Resistance Profiles
Plasma stability assays demonstrate CJC-1295's extended half-life characteristics in human and rodent plasma preparations. LC-MS/MS analysis reveals minimal degradation over 24-hour incubation periods at 37°C, attributed to drug affinity complex (DAC) modifications that reduce dipeptidyl peptidase-IV susceptibility.
Ipamorelin shows moderate plasma stability with approximately 60-70% compound remaining after 4-hour incubation periods in fresh human plasma. Primary degradation occurs through N-terminal amino acid cleavage, as identified through mass spectrometry fragmentation pattern analysis.
Cellular Uptake and Efflux Mechanisms
Transport studies in Caco-2 cell monolayers indicate minimal transcellular permeability for both compounds, consistent with peptidic molecular structures. P-glycoprotein interaction assays show negligible efflux pump recognition, suggesting limited active transport involvement in cellular distribution patterns.
Research Summary
Combined CJC-1295 and ipamorelin formulations demonstrate complementary receptor pharmacology through dual pathway activation in growth hormone axis signaling cascades. Ipamorelin's selective GHSR-1a engagement provides calcium-dependent pathway activation, while CJC-1295 delivers sustained GHRH receptor stimulation through cAMP-PKA signaling mechanisms. These distinct molecular targets and signaling preferences support continued investigation in appropriate in vitro model systems to characterize synergistic receptor activation patterns and downstream transcriptional responses in relevant cellular environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML